Business Context and Reporting Period
Company: REGENXBIO Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 19, 2016
Event: Announcement of preclinical data presentation at the American Society of Gene & Cell Therapy 19th Annual Meeting.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a specific corporate event rather than a periodic financial report.
Material Changes
No material financial changes are reported in this filing. The primary update is the scheduled presentation of preclinical study data supported by the Company at the Perelman School of Medicine at the University of Pennsylvania.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) confirming that preclinical data will be presented in two poster sessions at the upcoming industry conference.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K filing.
Investor Verification Checklist
- Verify the content of the press release filed as Exhibit 99.1 for details on the preclinical data.
- Confirm the specific dates and location of the American Society of Gene & Cell Therapy 19th Annual Meeting.
- Review subsequent filings for any updates on the clinical implications of the presented data.